Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.54 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583867 | 0.81 | TRPV3 (0.38) | TRPV3CCR1 | |
| SCHEMBL14636042 | 0.81 | TRPV3 (0.50) | TRPV3CYP4A11FFAR4CYP4F2KCNH2 | |
| SCHEMBL2522651 | 0.80 | TRPV3 (0.45) | TRPV3FFAR4KCNH2ALOX5APNPSR1 | |
| SCHEMBL19542 | 0.79 | KDM1A (0.44) | TRPV3CCR1MPOKDM1AMAOA | |
| SCHEMBL31108353 | 0.77 | TRPV3 (0.35) | TRPV3CCR1 | |
| SCHEMBL5756021 | 0.77 | TRPV3 (0.38) | TRPV3CCR1RXRAGRIN1GRIN2B | |
| SCHEMBL20730070 | 0.77 | PPARA (0.47) | TRPV3CYP4A11CYP4F2 | |
| SCHEMBL1536741 | 0.76 | MAPK8 (0.50) | TRPV3CCR1P2RX3 | |
| SCHEMBL12538133 | 0.75 | TRPV3 (0.65) | TRPV3 | |
| SCHEMBL13141152 | 0.75 | DDB1 (0.37) | TRPV3CYP4A11CYP4F2ALOX5APNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569317-B2 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-7696216-B2 | Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20100063075-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | ALTMANN EVA | 2010-03-11 | — | — | US | disclosed |
| CN-101445486-A | Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone | NOVARTIS PHARMA AG (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-1585521-B8 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| EP-1585521-B1 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1844780-A2 | Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone | Novartis Pharma AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2006-04-13 | — | — | US | disclosed |
| CN-1732002-A | Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives for promoting parathyroid hormone release | NOVARTIS AG (CH) | 2006-02-08 | — | — | CN | disclosed |
| EP-1585521-A2 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004056365-A2 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | TRPV3 716/4885CCR1 3365/4885CYP4A11 141/4885 |
| US-20100063075-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | TRPV3 712/4885CCR1 3245/4885CYP4A11 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.